EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Artelo Biosciences's Enterprise Value is $-6.05 Mil.
Artelo Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.21 Mil. Therefore, Artelo Biosciences's EV-to-FCF for today is 0.74.
The historical rank and industry rank for Artelo Biosciences's EV-to-FCF or its related term are showing as below:
ARTL'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.4 Med: 0 Max: 1.35
Current: 0.74
During the past 10 years, the highest EV-to-FCF of Artelo Biosciences was 1.35. The lowest was -3.40. And the median was 0.00.
ARTL's EV-to-FCF is ranked better than 68.37% of 392
companies
in the Biotechnology industry
Industry Median: 4.57
vs ARTL: 0.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Artelo Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Artelo Biosciences's EV-to-FCF
For the Biotechnology subindustry, Artelo Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's EV-to-FCF falls into.
Artelo Biosciences's current Enterprise Value is $-6.05 Mil.
Artelo Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Artelo Biosciences's PE Ratio for today is calculated as:
Artelo Biosciences's share price for today is $1.35.
Artelo Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.140.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Artelo Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Artelo Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Artelo Biosciences (Artelo Biosciences) Business Description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARTL has been successfully added to your 